Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (161-170 of 246) with videos related to

Pageof 25
Sort By:
RMD Open|July 6, 2021
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinibKurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, et al.
Arthritis and Rheumatism|March 6, 2013
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritisSabrina R Kapoor, Andrew Filer, Martin A Fitzpatrick, et al.
Advances in Therapy|July 11, 2025
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C Taylor, Thomas Bieber, Rieke Alten, et al.
Journal of Clinical Medicine|September 8, 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAMBruno Fautrel, Bruce Kirkham, Janet E Pope, et al.
British Journal of Haematology|April 27, 2012
Diagnosis and management of chronic graft-versus-host diseaseFiona L Dignan, Persis Amrolia, Andrew Clark, et al.
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Resuscitation|February 22, 2023
Preclinical evaluation of triiodothyronine nanoparticles as a novel therapeutic intervention for resuscitation from cardiac arrestBrian R Weil, Shannon E Allen, Thomas Barbaccia, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
Seminars in Arthritis and Rheumatism|October 9, 2023
Teleconsultation in rheumatology: A literature review and opinion paperJérôme Avouac, Hubert Marotte, Alejandro Balsa, et al.
Patient Preference and Adherence|October 17, 2018
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practicePeter C Taylor, Rieke Alten, Juan J Gomez Reino, et al.
Pageof 25

Showing results (161-170 of 246) with videos related to

Sort By:
Pageof 25
RMD Open|July 6, 2021
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinibKurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, et al.
Arthritis and Rheumatism|March 6, 2013
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritisSabrina R Kapoor, Andrew Filer, Martin A Fitzpatrick, et al.
Advances in Therapy|July 11, 2025
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C Taylor, Thomas Bieber, Rieke Alten, et al.
Journal of Clinical Medicine|September 8, 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAMBruno Fautrel, Bruce Kirkham, Janet E Pope, et al.
British Journal of Haematology|April 27, 2012
Diagnosis and management of chronic graft-versus-host diseaseFiona L Dignan, Persis Amrolia, Andrew Clark, et al.
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Resuscitation|February 22, 2023
Preclinical evaluation of triiodothyronine nanoparticles as a novel therapeutic intervention for resuscitation from cardiac arrestBrian R Weil, Shannon E Allen, Thomas Barbaccia, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
Seminars in Arthritis and Rheumatism|October 9, 2023
Teleconsultation in rheumatology: A literature review and opinion paperJérôme Avouac, Hubert Marotte, Alejandro Balsa, et al.
Patient Preference and Adherence|October 17, 2018
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practicePeter C Taylor, Rieke Alten, Juan J Gomez Reino, et al.
Pageof 25